NCT00264290View on ClinicalTrials.gov

Valganciclovir to Reduce T Cell Activation in HIV Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

November 30, 2008

Conditions
HIV InfectionsCytomegalovirus Infections
Interventions
DRUG

Valganciclovir

900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.

DRUG

Placebo

Placebo designed to resemble Valganciclovir

Trial Locations (1)

94110

San Francisco General Hospital - General Clinical Research Center, San Francisco

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT00264290 - Valganciclovir to Reduce T Cell Activation in HIV Infection | Biotech Hunter | Biotech Hunter